PAR-2 inhibition reverses experimental pulmonary hypertension

Circulation Research

Volumn 110, Issue 9, 2012, Pages 1179-1191

  Kwapiszewska, Grazyna ^a,b   Markart, Philipp ^a   Dahal, Bhola Kumar ^a   Kojonazarov, Baktybek ^a   Marsh, Leigh Matthew ^b   Schermuly, Ralph Theo ^a   Taube, Christian ^c   Meinhardt, Andreas ^a   Ghofrani, Hossein Ardeschir ^a   Steinhoff, Martin ^d   Seeger, Werner ^a   Preissner, Klaus Theo ^a   Olschewski, Andrea ^b   Weissmann, Norbert ^a   Wygrecka, Malgorzata ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Mast cells; Protease activated receptor 2; Pulmonary arterial hypertension

Indexed keywords

FIBRONECTIN; GELATINASE A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCROTALINE; PLATELET DERIVED GROWTH FACTOR BB; PROTEINASE ACTIVATED RECEPTOR 2; TRYPTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; LUNG; LUNG BLOOD VESSEL; MALE; MAST CELL; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TREATMENT RESPONSE; UPREGULATION;

ADOLESCENT; ADULT; ANIMALS; ANOXIA; ANTIBODIES, NEUTRALIZING; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIGANDS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; MONOCROTALINE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OLIGOPEPTIDES; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-SIS; PULMONARY ARTERY; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, PAR-2; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TRYPTASES; YOUNG ADULT;

EID: 84860710320     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.111.257568     Document Type: Article

References (44)

1. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:13S-24S.
2. Smirnov SV, Robertson TP, Ward JP, Aaronson PI. Chronic hypoxia is associated with reduced delayed rectifier k current in rat pulmonary artery muscle cells. Am J Physiol. 1994;266:H365-H370.
3. Beppu H, Ichinose F, Kawai N, Jones RC, Yu PB, Zapol WM, Miyazono K, Li E, Bloch KD. Bmpr-ii heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. Am J Physiol Lung Cell Mol Physiol. 2004;287: L1241-L1247.
4. Fike CD, Zhang Y, Kaplowitz MR. Thromboxane inhibition reduces an early stage of chronic hypoxia-induced pulmonary hypertension in piglets. J Appl Physiol. 2005;99:670-676.
5. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994;75:539-545.
6. Tuder RM, Voelkel NF. Pulmonary hypertension and inflammation. J Lab Clin Med. 1998;132:16-24.
7. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J. 2003;22:358-363.
8. Mitani Y, Ueda M, Maruyama K, Shimpo H, Kojima A, Matsumura M, Aoki K, Sakurai M. Mast cell chymase in pulmonary hypertension. Thorax. 1999;54:88-90.
9. Schwartz LB. Monoclonal antibodies against human mast cell tryptase demonstrate shared antigenic sites on subunits of tryptase and selective localization of the enzyme to mast cells. J Immunol. 1985;134:526-531.
10. Sommerhoff CP, Bode W, Matschiner G, Bergner A, Fritz H. The human mast cell tryptase tetramer: a fascinating riddle solved by structure. Biochim Biophys Acta. 2000;1477:75-89.
11. Cairns JA, Walls AF. Mast cell tryptase is a mitogen for epithelial cells. Stimulation of il-8 production and intercellular adhesion molecule-1 expression. J Immunol. 1996;156:275-283.
12. Gruber BL, Kew RR, Jelaska A, Marchese MJ, Garlick J, Ren S, Schwartz LB, Korn JH. Human mast cells activate fibroblasts: tryptase is a fibrogenic factor stimulating collagen messenger ribonucleic acid synthesis and fibroblast chemotaxis. J Immunol. 1997;158:2310-2317.
13. Ruoss SJ, Hartmann T, Caughey GH. Mast cell tryptase is a mitogen for cultured fibroblasts. J Clin Invest. 1991;88:493-499.
14. Vergnolle N, Wallace JL, Bunnett NW, Hollenberg MD. Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci. 2001;22:146-152.
15. Bucci M, Roviezzo F, Cirino G. Protease-activated receptor-2 (par2) in cardiovascular system. Vascul Pharmacol. 2005;43:247-253.
16. Leger AJ, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation. 2006;114:1070-1077.
17. Schmidlin F, Amadesi S, Vidil R, Trevisani M, Martinet N, Caughey G, Tognetto M, Cavallesco G, Mapp C, Geppetti P, Bunnett NW. Expression and function of proteinase-activated receptor 2 in human bronchial smooth muscle. Am J Respir Crit Care Med. 2001;164:1276-1281.
18. Lan RS, Knight DA, Stewart GA, Henry PJ. Role of pge(2) in proteaseactivated receptor-1,-2 and-4 mediated relaxation in the mouse isolated trachea. Br J Pharmacol. 2001;132:93-100.
19. Cocks TM, Moffatt JD. Protease-activated receptor-2 (par2) in the airways. Pulm Pharmacol Ther. 2001;14:183-191.
20. Damiano BP, D'Andrea MR, de Garavilla L, Cheung WM, Andrade-Gordon P. Increased expression of protease activated receptor-2 (par-2) in balloon-injured rat carotid artery. Thromb Haemost. 1999;81:808-814.
21. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F. Reversal of experimental pulmonary hypertension by pdgf inhibition. J Clin Invest. 2005;115:2811-2821.
22. Vliagoftis H, Schwingshackl A, Milne CD, Duszyk M, Hollenberg MD, Wallace JL, Befus AD, Moqbel R. Proteinase-activated receptor-2-mediated matrix metalloproteinase-9 release from airway epithelial cells. J Allergy Clin Immunol. 2000;106:537-545.
23. Ramachandran R, Hollenberg MD. Proteinases and signalling: Pathophysiological and therapeutic implications via pars and more. Br J Pharmacol. 2008;153(suppl 1):S263-S282.
24. Tennant GM, Wadsworth RM, Kennedy S. Par-2 mediates increased inflammatory cell adhesion and neointima formation following vascular injury in the mouse. Atherosclerosis. 2008;198:57-64.
25. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med. 2005;353:1412-1413.
26. Kanke T, Kabeya M, Kubo S, Kondo S, Yasuoka K, Tagashira J, Ishiwata H, Saka M, Furuyama T, Nishiyama T, Doi T, Hattori Y, Kawabata A, Cunningham MR, Plevin R. Novel antagonists for proteinase-activated receptor 2: inhibition of cellular and vascular responses in vitro and in vivo. Br J Pharmacol. 2009;158:361-371.
27. Al-Ani B, Saifeddine M, Wijesuriya SJ, Hollenberg MD. Modified proteinase-activated receptor-1 and-2 derived peptides inhibit proteinaseactivated receptor-2 activation by trypsin. J Pharmacol Exp Ther. 2002; 300:702-708.
28. De Cunto G, Cardini S, Cirino G, Geppetti P, Lungarella G, Lucattelli M. Pulmonary hypertension in smoking mice over-expressing protease-activated receptor-2. Eur Respir J. 2011;37:823-834.
29. Price LC, Wort SJ, Perros F, Dorfmuller P, Huertas A, Montani D, Cohen-Kaminsky S, Humbert M. Inflammation in pulmonary arterial hypertension. Chest. 2012;141:210-221.
30. Williams A, Heath D, Kay JM, Smith P. Lung mast cells in rats exposed to acute hypoxia, and chronic hypoxia with recovery. Thorax. 1977;32:287-295.
31. Banasova A, Maxova H, Hampl V, Vizek M, Povysilova V, Novotna J, Vajnerova O, Hnilickova O, Herget J. Prevention of mast cell degranulation by disodium cromoglycate attenuates the development of hypoxic pulmonary hypertension in rats exposed to chronic hypoxia. Respiration. 2008;76:102-107.
32. Montani D, Perros F, Gambaryan N, Girerd B, Dorfmuller P, Price LC, Huertas A, Hammad H, Lambrecht B, Simonneau G, Launay JM, Cohen-Kaminsky S, Humbert M. C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2011;184:116-123.
33. Dahal BK, Kosanovic D, Kaulen C, Cornitescu T, Savai R, Hoffmann J, Reiss I, Ghofrani HA, Weissmann N, Kuebler WM, Seeger W, Grimminger F, Schermuly RT. Involvement of mast cells in monocrotalineinduced pulmonary hypertension in rats. Respir Res. 2011;12:60.
34. Hoffmann J, Yin J, Kukucka M, Yin N, Saarikko I, Sterner-Kock A, Fujii H, Leong-Poi H, Kuppe H, Schermuly RT, Kuebler WM. Mast cells promote lung vascular remodelling in pulmonary hypertension. Eur Respir J. 2011;37:1400-1410.
35. Bartelds B, van Loon RL, Mohaupt S, Wijnberg H, Dickinson M, Boersma B, Takens J, van Albada M, Berger RM. Mast cell inhibition improves pulmonary vascular remodeling in pulmonary hypertension. Chest. 2012;141:651-660.
36. Akers IA, Parsons M, Hill MR, Hollenberg MD, Sanjar S, Laurent GJ, McAnulty RJ. Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2. Am J Physiol Lung Cell Mol Physiol. 2000;278:L193-L201.
37. Brown JK, Tyler CL, Jones CA, Ruoss SJ, Hartmann T, Caughey GH. Tryptase, the dominant secretory granular protein in human mast cells, is a potent mitogen for cultured dog tracheal smooth muscle cells. Am J Respir Cell Mol Biol. 1995;13:227-236.
38. Liu Y, Mueller BM. Protease-activated receptor-2 regulates vascular endothelial growth factor expression in mda-mb-231 cells via mapk pathways. Biochem Biophys Res Commun. 2006;344:1263-1270.
39. Rattenholl A, Seeliger S, Buddenkotte J, Schon M, Schon MP, Stander S, Vergnolle N, Steinhoff M. Proteinase-activated receptor-2 (par2): a tumor suppressor in skin carcinogenesis. J Invest Dermatol. 2007;127:2245-2252.
40. Su X, Camerer E, Hamilton JR, Coughlin SR, Matthay MA. Proteaseactivated receptor-2 activation induces acute lung inflammation by neuropeptide-dependent mechanisms. J Immunol. 2005;175:2598-2605.
41. Seatter MJ, Drummond R, Kanke T, Macfarlane SR, Hollenberg MD, Plevin R. The role of the c-terminal tail in protease-activated receptor-2-mediated ca2 signalling, proline-rich tyrosine kinase-2 activation, and mitogen-activated protein kinase activity. Cell Signal. 2004;16:21-29.
42. Darmoul D, Gratio V, Devaud H, Laburthe M. Protease-activated receptor 2 in colon cancer: trypsin-induced mapk phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. JBiol Chem. 2004;279:20927-20934.
43. Koo B-H, Chung K-H, Hwang K-C, Kim D-S. Factor xa induces mitogenesis of coronary artery smooth muscle cell via activation of par-2. FEBS Lett. 2002;523:85-89.
44. Delbeck M, Nickel KF, Perzborn E, Ellinghaus P, Strassburger J, Kast R, Laux V, Schafer S, Schermuly RT, von Degenfeld G. A role for coagulation factor Xa in experimental pulmonary arterial hypertension. Cardiovasc Res. 2011;92:159-168.